FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0287			
Estimated average	burden			
hours per response.	0.5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * FLETCHER R JOHN			2. Issuer Name and Ticker or Trading Symbol ClearPoint Neuro, Inc. [CLPT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100 (Street) SOLANA BEACH, CA 92075			1000	3. Date of Earliest Transaction (Month/Day/Year) 06/25/2021 4. If Amendment, Date Original Filed(Month/Day/Year)							Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person uired, Disposed of, or Beneficially Owned				
			,							_X_					ne)
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqu						s Acquired					
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea			:	4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D) Owned Follo				Ownership Form: Direct (D)	Beneficial Ownership	
						Со	ode V		A) or (D)	Price		or Indirect (Instr (I) (Instr. 4)		(IIIStr. 4)	
Common	Stock (1)		06/25/2021			A	1	3,003 A		\$ 0 50				D	
Reminder:	Report on a s	separate fine for each	relass of securities	ochemena	ly owned t	meeny	Perso contai	ns who res	for	m are not	required	of informa to respond ntrol numb	d unless the		1474 (9-02)
1. Title of		3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivativ (e.g., puts 4. Transact Code	s, calls, wa 5. Nui ion of Deriva	mber ative eties red sed 3, 4,	Perso contai form c	ns who reaned in this lisplays a cosed of, or convertible arcisable an Date	Bene secur	n are not ently valid eficially Ov	required d OMB colored wned d Amount ving	to respondentrol numbers 8. Price of	d unless the	f 10. Ownersl Form of Derivati Security Direct (I or Indire	11. Natur of Indire Benefici Ownersl (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if	Derivativ (e.g., puts 4. Transact Code	se Securitis, calls, wa 5. Nur ion of Derive Securit Acqui (A) or Dispo of (D) (Instr.	mber ative eties red sed 3, 4,	Person contain form contain for contain form contain form contain form contain form contain for contain form contain form contain form contain form contain for contain form contain form contain form contain for contain form contain for con	ns who reined in this lisplays a cosed of, or convertible ercisable an Date y/Year)	Bene Bene dd	ently validation are not ently validation. efficially Owities) 7. Title and of Underly Securities	required d OMB colored wned d Amount ving	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersl Form of Derivati Security Direct (I or Indire s) (I)	11. Natur of Indire Benefici Ownersl (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
FLETCHER R JOHN C/O CLEARPOINT NEURO, INC. 120 S. SIERRA AVE., SUITE 100 SOLANA BEACH, CA 92075	X				

Signatures

/s/ Richard F. Mattern, by Power of Attorney for R. John Fletcher	06/28/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders
- (2) The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.